

Table 8

Histopathological findings in livers (1-year toxicity study)

Sex	Treatment	Dammar resin	No. of animal	Bile duct hyperplasia			Inflammatory cell infiltration		Microgranuloma		
				0	1	2	3	-	+	-	+
Male	Control		10	0	0	7	3	6	4	7	3
	0.03%		10	0	0	7	3	8	2	9	1
	0.125%		10	0	0	8	2	6	4	8	2
	0.5%		10	0	1	9	0	7	3	10	0
	2%		10	8*	2	0	0	5	5	10	0
Female	Control		10	7	3	0	0	7	3	6	4
	0.03%		10	8	2	0	0	6	4	6	4
	0.125%		10	7	2	1	0	8	2	6	4
	0.5%		10	9	1	0	0	8	2	9	1
	2%		10	10	0	0	0	6	4	9	1

0, negative; 1, slight; 2, moderate; 3, extensive.

* Significantly different from control group.

Table 9

Development of GST-P positive foci in livers of male rats (1-year toxicity study)

Treatment	No. of animal	No. of GST-P positive foci /cm ² (no. of rat)				Total
		Diameter \square 0.1 mm, <0.2 mm	Diameter \square 0.2 mm, <0.4 mm	Diameter \square 0.4mm	Diameter \square 0.4mm	
Control	10	1.6 \pm 1.4 (9)	0.4 \pm 0.5 (6)	0 (0)	0 (0)	2.1 \pm 1.8 (9)
0.03%	10	0.8 \pm 0.6 (9)	0.1 \pm 0.5 (1)	0 (0)	0 (0)	0.9 \pm 0.8 (9)
0.125%	10	1.0 \pm 0.9 (8)	0.3 \pm 0.4 (4)	0 (0)	0 (0)	1.2 \pm 0.9 (9)
0.5%	10	0.9 \pm 0.5 (9)	0.4 \pm 0.9 (5)	0 (0)	0 (0)	1.4 \pm 1.3 (9)
2%	10	1.2 \pm 0.8 (9)	0.5 \pm 0.3 (9)	0.1 \pm 0.2 (2)	0.1 \pm 0.2 (2)	1.8 \pm 0.9 (10)

Table 10

Expression of GST-P in livers of female rats (1-year toxicity study)

Treatment	No. of animal	GST-P positive foci classification			
		0	1	2	3
Dammar resin					
Control	10	3	7	0	0
0.03%	10	0	10	0	0
0.125%	10	0	9	1	0
0.5%	10	0	2	3	5*
2%	10	0	0	0	10*

0, negative; 1, slight; 2, moderate; 3, extensive

* Number of class-3 liver significantly different from control group.

Table 11
 Histopathological findings in kidney (1-year toxicity study)

	Dose (%)	Male					Female					
		0	0.125	0.125	0.5	2	0	0.125	0.125	0.5	0.5	2
Protein cast	No. of rats examined	<10> ^a	<10>	<10>	<10>	<10>	<10>	<10>	<10>	<10>	<10>	<10>
	+	1	2	6	3	4	0	-	-	-	-	0
	2+	0	0	0	4	5*	0	-	-	-	-	0
	Positive (Total)	1	2	6	7*	9*	0	-	-	-	-	0
Tubular dilatation	+	0	0	0	1	3	0	-	-	-	-	0
	2+	0	0	0	1	1	0	-	-	-	-	0
	Positive (Total)	0	0	0	2	4	0	-	-	-	-	0

^a, no examined.

* Significantly different from control group.

Table 12

Histopathological findings in organs other than liver and kidney (1-year toxicity study)

Organ/Finding	Dose (%)	Male					Female				
		0	0.125	0.5	0.5	2	0	0.125	0.5	0.5	2
<i>Spleen</i>		<10> ^a	-	-	-	<10>	<10>	-	-	-	<10>
Pigment deposition		10	-	-	-	10	10	-	-	-	10
<i>Pancreas</i>		<10>	-	-	-	<10>	<10>	-	-	-	<10>
Inflammatory cell infiltration		4	-	-	-	3	4	-	-	-	1
Proliferation, pancreatic duct		0	-	-	-	2	0	-	-	-	0
Vacuolation, acinar cell		0	-	-	-	0	1	-	-	-	2
<i>Prostate</i>		<10>	-	-	-	<10>	-	-	-	-	-
Inflammatory cell infiltration		2	-	-	-	1	-	-	-	-	-
<i>Pituitary</i>		<10>	-	-	-	<10>	<9>	-	-	-	<10>
Cyst		1	-	-	-	0	0	-	-	-	0
Cyst like lesion		0	-	-	-	0	3	-	-	-	2
<i>Thyroid</i>		<10>	-	-	-	<10>	<9>	-	-	-	<10>
Ultrabronchial body		1	-	-	-	0	0	-	-	-	2
C-cell hyperplasia		1	-	-	-	2	0	-	-	-	0

^a Number of rats examined; -, no examined.

Table 13

Summary of average body weight (g) and number of surviving rats (2-year carcinogenicity study)

Dammar resin	WEEK 0	WEEK 1	WEEK 2	WEEK 3	WEEK 4
Male					
Control	(50) ^a 113 ± 6	(50) 162 ± 9	(50) 196 ± 10	(50) 222 ± 11	(50) 241 ± 12
0.03%	(50) 113 ± 5	(50) 164 ± 9	(50) 199 ± 9	(50) 228 ± 9 *	(50) 246 ± 10 *
0.5%	(50) 113 ± 6	(50) 164 ± 8	(50) 200 ± 9	(50) 228 ± 9 *	(50) 249 ± 9 *
2%	(50) 113 ± 6	(50) 156 ± 9 *	(50) 190 ± 12 *	(50) 217 ± 12 *	(50) 235 ± 13
Female					
Control	(50) 94 ± 4	(50) 118 ± 4	(50) 132 ± 5	(50) 141 ± 6	(50) 146 ± 6
0.03%	(50) 94 ± 5	(50) 118 ± 5	(50) 133 ± 6	(50) 143 ± 5	(50) 149 ± 6
0.5%	(50) 94 ± 4	(50) 118 ± 6	(50) 134 ± 5	(50) 144 ± 7 *	(50) 151 ± 6 *
2%	(50) 94 ± 4	(50) 115 ± 5 *	(50) 131 ± 5 *	(50) 141 ± 5	(50) 146 ± 6

^a Number of surviving rat

* Significantly different from corresponding control group.

Table 13 (Continued)

Summary of average body weight (g) and number of surviving rats (2-year carcinogenicity study)

Dammar resin	WEEK 5	WEEK 6	WEEK 7	WEEK 8	WEEK 9
Male					
Control	(50) 261 ± 13	(50) 276 ± 14	(50) 288 ± 15	(50) 299 ± 16	(50) 309 ± 16
0.03%	(50) 267 ± 11 *	(50) 284 ± 12 *	(50) 299 ± 13 *	(50) 310 ± 14 *	(50) 321 ± 14 *
0.5%	(50) 270 ± 10 *	(50) 287 ± 11 *	(50) 300 ± 12 *	(50) 313 ± 13 *	(50) 323 ± 13 *
2%	(50) 254 ± 14 *	(50) 269 ± 15 *	(50) 282 ± 16	(50) 292 ± 16 *	(50) 302 ± 18
Female					
Control	(50) 159 ± 7	(50) 165 ± 7	(50) 169 ± 7	(50) 173 ± 7	(50) 177 ± 7
0.03%	(50) 161 ± 7	(50) 168 ± 7	(50) 172 ± 8	(50) 177 ± 7 *	(50) 181 ± 7 *
0.5%	(50) 161 ± 7	(50) 168 ± 8	(50) 173 ± 8	(50) 176 ± 8	(50) 180 ± 8
2%	(50) 156 ± 6	(50) 162 ± 6 *	(50) 167 ± 6	(50) 169 ± 6	(50) 173 ± 6 *

* Significantly different from corresponding control group.

Table 13 (Continued)

Summary of average body weight (g) and number of surviving rats (2-year carcinogenicity study)

Dammar resin	WEEK 21	WEEK 25	WEEK 29	WEEK 33	WEEK 37
Male					
Control	(50) 371 ± 20	(50) 388 ± 21	(50) 400 ± 21	(50) 409 ± 22	(50) 419 ± 21
0.03%	(50) 396 ± 20 *	(50) 413 ± 21 *	(50) 426 ± 22 *	(50) 438 ± 22 *	(49) 449 ± 24*
0.5%	(50) 391 ± 18 *	(50) 406 ± 17 *	(50) 419 ± 19 *	(50) 429 ± 19 *	(50) 438 ± 19*
2%	(50) 360 ± 21 *	(50) 372 ± 20 *	(50) 378 ± 21 *	(50) 387 ± 21 *	(50) 393 ± 21*
Female					
Control	(49) 195 ± 8	(49) 201 ± 9	(49) 204 ± 9	(49) 205 ± 8	(49) 211 ± 9
0.03%	(50) 202 ± 8 *	(50) 210 ± 8 *	(50) 214 ± 9 *	(50) 216 ± 10 *	(50) 222 ± 10
0.5%	(50) 198 ± 9	(50) 204 ± 9	(50) 208 ± 9 *	(50) 212 ± 10 *	(50) 216 ± 10
2%	(50) 190 ± 6 *	(50) 195 ± 7 *	(50) 198 ± 7 *	(50) 201 ± 7	(50) 205 ± 8

* Significantly different from corresponding control group.

Table 13 (Continued)

Summary of average body weight (g) and number of surviving rats (2-year carcinogenicity study)

	WEEK 41	WEEK 45	WEEK 49	WEEK 53	WEEK 58
Male					
Control	(50) 426 ± 23	(50) 434 ± 23	(50) 440 ± 24	(50) 447 ± 25	(50) 450 ± 26
0.03%	(49) 458 ± 24 *	(49) 463 ± 23 *	(49) 470 ± 24 *	(49) 475 ± 26 *	(49) 480 ± 27 *
0.5%	(50) 447 ± 19 *	(49) 452 ± 20 *	(49) 458 ± 21 *	(49) 461 ± 23 *	(49) 466 ± 24 *
2%	(50) 400 ± 21 *	(50) 405 ± 22 *	(50) 410 ± 22 *	(50) 413 ± 23 *	(50) 416 ± 22 *
Female					
Control	(49) 215 ± 9	(49) 219 ± 10	(49) 222 ± 11	(49) 227 ± 11	(49) 232 ± 12
0.03%	(50) 229 ± 11 *	(50) 233 ± 12 *	(50) 237 ± 12 *	(50) 241 ± 13 *	(49) 249 ± 19 *
0.5%	(50) 221 ± 10 *	(50) 226 ± 11 *	(50) 231 ± 11 *	(50) 236 ± 12 *	(50) 242 ± 14 *
2%	(50) 208 ± 8 *	(50) 211 ± 9 *	(50) 213 ± 9 *	(50) 217 ± 9 *	(49) 220 ± 10 *

* Significantly different from corresponding control group.

Table 13 (Continued)

Summary of average body weight (g) and number of surviving rats (2-year carcinogenicity study)

	WEEK 61	WEEK 65	WEEK 69	WEEK 73	WEEK 77
Male					
Control	(50) 453 ± 27	(50) 457 ± 26	(50) 465 ± 28	(50) 468 ± 28	(50) 472 ± 29
0.03%	(49) 484 ± 28 *	(49) 486 ± 34 *	(48) 495 ± 30 *	(47) 504 ± 32 *	(47) 506 ± 31 *
0.5%	(49) 468 ± 25 *	(49) 470 ± 26	(49) 477 ± 28	(49) 482 ± 29 *	(49) 483 ± 28
2%	(50) 419 ± 23 *	(49) 421 ± 25 *	(47) 427 ± 22 *	(45) 431 ± 23 *	(45) 433 ± 24 *
Female					
Control	(49) 234 ± 13	(48) 237 ± 15	(48) 244 ± 18	(47) 251 ± 20	(46) 260 ± 21
0.03%	(48) 252 ± 19 *	(48) 255 ± 22 *	(46) 264 ± 22 *	(46) 273 ± 24 *	(46) 283 ± 25 *
0.5%	(50) 244 ± 16 *	(50) 247 ± 17 *	(50) 254 ± 18 *	(50) 262 ± 20 *	(50) 271 ± 22 *
2%	(49) 222 ± 10 *	(49) 223 ± 11 *	(49) 228 ± 12 *	(49) 233 ± 14 *	(49) 238 ± 15 *

* Significantly different from corresponding control group.

Table 13 (Continued)

Summary of average body weight (g) and number of surviving rats (2-year carcinogenicity study)

	WEEK 81	WEEK 85	WEEK 89	WEEK 93	WEEK 97
Male					
Control	(48) 476 ± 28	(47) 476 ± 28	(45) 486 ± 33	(44) 479 ± 28	(43) 478 ± 27
0.03%	(47) 507 ± 32 *	(46) 504 ± 32 *	(45) 508 ± 33 *	(45) 501 ± 34 *	(44) 493 ± 37
0.5%	(48) 485 ± 28	(47) 483 ± 27	(45) 486 ± 24	(43) 478 ± 25	(42) 475 ± 27
2%	(44) 436 ± 24 *	(44) 433 ± 24 *	(42) 440 ± 25 *	(41) 438 ± 26 *	(37) 431 ± 22 *
Female					
Control	(45) 264 ± 24	(44) 270 ± 25	(44) 275 ± 26	(42) 282 ± 28	(40) 286 ± 25
0.03%	(46) 290 ± 25 *	(46) 297 ± 26 *	(46) 306 ± 27 *	(45) 311 ± 28 *	(45) 315 ± 28 *
0.5%	(50) 277 ± 22 *	(50) 283 ± 24 *	(50) 291 ± 26 *	(50) 292 ± 26	(48) 294 ± 27
2%	(48) 243 ± 14 *	(48) 247 ± 16 *	(48) 255 ± 17 *	(47) 257 ± 17 *	(47) 260 ± 18 *

* Significantly different from corresponding control group.

Table 13 (Continued)

Summary of average body weight (g) and number of surviving rats (2-year carcinogenicity study)

	WEEK 101	WEEK 103	WEEK 104
Male			
Control	480 ± 30 (43)	471 ± 32 (43)	471 ± 34 (43)
0.03%	493 ± 37 (41)	482 ± 43 (41)	481 ± 44 (41)
0.5%	470 ± 25 (40)	458 ± 27 (40)	456 ± 27 (40)
2%	431 ± 25 * (29)	421 ± 26 * (27)	417 ± 29 * (22)
Female			
Control	288 ± 25 (40)	283 ± 26 (37)	283 ± 26 (37)
0.03%	319 ± 30 * (44)	317 ± 31 * (43)	316 ± 31 * (43)
0.5%	298 ± 28 (47)	292 ± 28 (47)	292 ± 29 (46)
2%	265 ± 19 * (43)	262 ± 22 * (42)	261 ± 22 * (42)

* Significantly different from corresponding control group.

Table 14

Food intake (g/day/rat) in 2-year carcinogenicity study

Sex	Treatment	Week											
		1	2	3	4	5	6	7	8	9	10	11	12
Male	Control	12.6	14.0	15.0	14.9	15.3	14.5	14.3	14.2	13.9	13.2	13.7	13.1
	0.03%	13.2 *	14.6 *	15.5 *	15.7 *	16.3 *	15.4 *	15.3 *	15.1 *	14.8 *	14.2 *	14.5 *	13.8 *
	0.5%	13.6 *	15.1 *	16.1 *	16.1 *	16.6 *	15.6 *	15.7 *	15.5 *	15.0 *	14.4 *	14.6 *	14.0 *
	2%	12.9	14.6 *	15.5	15.4	15.9 *	15.2 *	14.7	14.9 *	14.3 *	13.7 *	14.0	13.2
Female	Control	9.7	7.1	10.1	9.3	10.1	9.8	9.3	9.1	10.2	8.7	9.0	8.6
	0.03%	10.2 *	9.4 *	10.5	10.2 *	10.5	10.0	9.7 *	9.7 *	9.5	9.1 *	9.3 *	8.9
	0.5%	10.5 *	10.2 *	10.3	10.3 *	10.5 *	9.9	9.7 *	9.6 *	9.2	8.9	9.0	8.8
	2%	10.2 *	9.9 *	10.2	9.7	9.9	9.9	9.2	9.2	9.0	8.4	9.1	8.6

* Significantly different from corresponding control group.

Table 14 (Continued)
Food intake (g/day/rat) in 2-year carcinogenicity study

Sex	Treatment	Week												
		13	14	18	22	26	30	34	38	42	46	50	54	
Male	Control	13.0	12.9	13.7	13.6	13.9	13.5	13.3	13.3	13.3	13.7	13.7	13.5	
	0.03%	14.0 *	13.7 *	15.0 *	14.8 *	15.0 *	14.5 *	14.3 *	14.5 *	14.6 *	14.6 *	14.7 *	14.4 *	
	0.5%	14.0 *	13.6 *	15.2 *	14.4 *	14.8 *	15.2 *	14.3 *	14.4 *	14.2 *	14.2 *	14.6 *	14.1 *	
	2%	13.7	13.0	14.8 *	13.4	14.9 *	14.3 *	14.3	14.2 *	14.5 *	14.5 *	14.4 *	14.0	
Female	Control	8.5	8.0	8.4	8.2	8.2	8.3	7.8	8.2	8.2	8.4	8.8	8.8	
	0.03%	9.1 *	8.4 *	9.0 *	8.7 *	9.1 *	8.5	8.5 *	8.8 *	8.7 *	8.7	9.2 *	9.1	
	0.5%	9.1 *	7.9	8.8 *	8.2	8.7 *	8.6 *	8.2 *	8.4	8.6	8.6	9.4 *	9.2 *	
	2%	8.7	7.8	8.5	8.2	8.5	8.4	8.2	8.5	8.4	8.4	8.7	9.0	

* Significantly different from corresponding control group.

Table 14 (Continued)

Food intake (g/day/rat) in 2-year carcinogenicity study

Sex	Treatment	Week												
		59	62	66	70	74	78	82	86	90	94	98	102	104
Male	Control	13.3	13.2	13.3	14.2	14.0	13.4	14.0	14.1	13.7	13.6	13.8	13.4	12.5
	0.03%	14.4 *	14.2 *	13.8 *	15.1 *	15.3 *	14.9 *	14.9 *	14.9	14.4 *	14.1	13.5	13.8	12.7
	0.5%	14.3 *	13.9 *	13.8 *	15.0 *	14.6 *	14.5 *	14.6	14.3	13.6	13.9	14.0	13.8	12.6
	2%	14.1 *	13.6 *	13.5	14.6	14.7 *	14.0 *	14.5	14.4	14.4 *	14.3	14.3	14.0	11.4
Female	Control	9.2	8.5	8.8	9.1	9.6	9.4	9.4	9.5	9.7	9.5	9.9	9.6	8.8
	0.03%	9.8	8.6	8.9	9.8 *	10.3 *	10.1 *	10.1	10.0	10.3	10.0	10.2	9.8	9.1
	0.5%	9.4	8.7	8.9	9.4 *	10.1	10.0 *	9.7	9.9	9.7	9.9	9.8	9.8	8.8
	2%	9.4	8.5	8.7	9.1	9.5	9.5	9.5	9.7	9.7	9.8	9.6	9.8	9.3

* Significantly different from corresponding control group.

Table 15

Intake of dammar resin of F344 rats in 2-year toxicity study

Sex	Treatment	Dammar resin	Total intake of dammar resin (mg/kg b.w.)	Average intake of dammar resin (mg/kg b.w./day)
Male	Control		0	0
	0.03%		7639.80	10.49
	0.5%		129786.93	178.28
	2%		558269.67	766.85
Female	Control		0	0
	0.03%		8874.67	12.19
	0.5%		149549.75	205.43
	2%		631947.19	868.06

Table 16

Water intake (g/day/rat) in 2-year carcinogenicity study

Sex	Treatment	Week											
		1	2	3	4	5	6	7	8	9	10	11	12
Male	Control	19.3	20.4	21.4	21.5	20.9	21.4	20.1	20.3	20.4	19.8	19.7	18.9
	0.03%	20.2	21.3	22.6	22.8 *	21.9	22.2	21.1 *	21.0	21.1	21.0 *	20.2	19.6
	0.5%	20.8 *	22.9 *	24.2 *	23.7 *	22.7 *	23.2 *	21.6 *	21.8 *	21.9 *	21.6 *	21.2 *	20.2 *
	2%	20.1	21.7	23.2 *	23.7 *	22.9 *	24.4 *	22.3 *	23.1 *	23.3 *	22.7 *	22.1 *	21.0 *
Female	Control	17.4	17.6	17.0	17.5	17.9	17.4	16.4	16.4	17.2	16.2	16.7	15.2
	0.03%	17.0	17.3	17.0	17.4	17.4	16.6	15.8	16.1	16.7	16.4	16.2	14.8
	0.5%	16.8	17.1	16.8	16.7	16.9	16.3	15.4	15.7	16.4	15.9	16.4	15.1
	2%	15.3 *	16.1 *	17.4 *	17.7	18.6	17.5	16.1	17.0	17.7	17.0	18.1 *	15.5

* Significantly different from corresponding control group.

Table 16 (Continued)
 Water intake (g/day/rat) in 2-year carcinogenicity study

Sex	Treatment	Week												
		13	14	18	22	26	30	34	38	42	46	50	54	
Male	Control	19.4	18.2	18.0	17.4	16.0	15.4	15.1	15.6	15.4	15.7	16.0	16.4	
	0.03%	20.5	18.8	18.4	17.8	16.7	16.0	15.9	16.1	15.9	16.1	16.8 *	17.4 *	
	0.5%	20.9 *	19.2	18.8	18.3	16.9 *	16.3 *	16.2 *	16.2 *	16.2 *	15.9	16.6	17.2 *	
	2%	22.6 *	21.2 *	21.0 *	20.9 *	19.0 *	18.2 *	17.6 *	17.6 *	17.7 *	17.5 *	17.8 *	18.5 *	
Female	Control	15.7	15.0	14.4	15.3	13.3	13.1	13.1	13.2	11.8	12.9	12.9	13.6	
	0.03%	15.4	14.4	14.1	14.7	12.8	12.6	12.8	13.1	11.7	12.5	12.7	13.7	
	0.5%	15.3 *	14.5	13.6	14.4	12.8	12.6	12.3 *	12.6	11.4	12.6	12.8	13.3	
	2%	16.3	15.2	14.4	16.2	13.4	12.9	13.2	13.6	11.4	13.1	12.7	13.8	

* Significantly different from corresponding control group.

Table 16 (Continued)
Water intake (g/day/rat) in 2-year carcinogenicity study

Sex	Treatment	Week												
		59	62	66	70	74	78	82	86	90	94	98	102	104
Male	Control	17.1	17.3	17.3	17.4	16.6	15.7	16.5	17.0	17.0	17.8	18.2	19.4	21.2
	0.03%	18.3 *	18.7 *	18.6 *	18.7 *	17.9 *	16.9 *	17.3 *	18.3 *	18.6 *	19.2 *	19.5 *	21.1 *	22.4 *
	0.5%	18.0 *	18.4 *	19.1 *	18.8 *	17.5 *	17.3 *	17.5 *	17.8 *	18.4 *	19.2 *	20.1 *	22.5 *	24.8 *
	2%	20.0 *	19.8 *	19.9 *	19.7 *	18.2 *	17.0 *	17.0 *	18.2 *	18.9 *	19.5 *	18.7 *	20.3 *	21.2 *
Female	Control	13.5	14.2	14.5	13.9	14.6	13.2	13.1	13.6	14.1	13.9	14.4	14.7	15.7
	0.03%	12.8 *	13.8 *	14.3 *	13.9 *	14.5 *	13.2 *	13.6 *	14.3 *	16.6 *	13.8 *	14.0 *	14.9 *	16.0 *
	0.5%	12.8 *	14.0 *	14.2 *	13.9 *	15.0 *	13.3 *	13.0 *	13.4 *	14.0 *	14.5 *	14.5 *	15.1 *	16.0 *
	2%	13.1 *	14.6 *	14.8 *	14.3 *	15.1 *	13.5 *	13.0 *	13.6 *	14.7 *	15.0 *	14.9 *	15.8 *	17.1 *

* Significantly different from corresponding control group.

Table 17A

Hematology data (2-year carcinogenicity study)

Treatment	No. of rats rat examined	RBC $\times 10^4/\mu\text{l}$	Hb g/dl	Ht %	PLT $\times 10^4/\mu\text{l}$
Male					
Control	17	873 \pm 135	14.6 \pm 2.4	48.5 \pm 7.3	65.8 \pm 8.1
0.03%	10	851 \pm 40	14.3 \pm 0.5	48.1 \pm 1.1	61.5 \pm 4.0
0.5%	9	867 \pm 41	14.4 \pm 0.7	49.1 \pm 2.7	70.7 \pm 4.9
2%	17	747 \pm 107 *	11.9 \pm 1.9 *	42.2 \pm 5.8 *	76.2 \pm 11.4 *
Female					
Control	10	794 \pm 54	14.4 \pm 1.3	44.9 \pm 3.2	52.2 \pm 9.0
0.03%	10	790 \pm 32	14.2 \pm 0.5	44.9 \pm 1.8	50.6 \pm 8.0
0.5%	10	784 \pm 33	14.0 \pm 1.5	45.1 \pm 4.1	58.3 \pm 12.5
2%	10	785 \pm 44	13.6 \pm 1.0	45.4 \pm 3.2	69.4 \pm 5.4 *

* Significantly different from control group.